Tesaro (TSRO) PT Raised to $139 at Wedbush

Wedbush analyst David Nierengarten reiterated an Outperform rating and boosted his price target on Tesaro (NASDAQ: TSRO) to $139.00 (from $107.00) as the NOVA trial data supports possible approval in all platinum-sensitive patients.

Nierengarten commented, "We see the clinical benefit of niraparib in HRD-negative patients as likely leading to approval in the entire platinum-sensitive ovarian market. Furthermore, we see the lack of requirement for a companion diagnostic for niraparib in these patients as a potential advantage over competing PARP inhibitors."

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $99.26 yesterday.

You May Also Be Interested In

• Alcon Inc. (ALC) PT Raised to $101 at Needham
• Garmin Ltd. (GRMN) PT Raised to $210 at Tigress Financial Partners
• Diageo plc (DEO) PT Lowered to $140 at CFRA